Is tadalafil associated with decreased risk of major adverse cardiac events or venous thromboembolism in men with lower urinary tract symptoms?

PURPOSE: To evaluate the association of tadalafil, a phosphodiesterase-5 inhibitor (PDE5I), with major adverse cardiac events (MACE) or venous thromboembolism (VTE) in men with lower urinary tract symptoms (LUTS). METHODS: Data was obtained from the TriNetX Research Network, ICD-10 codes were used t...

Descripción completa

Detalles Bibliográficos
Autores principales: Goberdhan, Sankalp, Blachman-Braun, Ruben, Nackeeran, Sirpi, Masterson, Thomas A., Ramasamy, Ranjith
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9037966/
https://www.ncbi.nlm.nih.gov/pubmed/35469100
http://dx.doi.org/10.1007/s00345-022-04005-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9037966/
https://www.ncbi.nlm.nih.gov/pubmed/35469100
http://dx.doi.org/10.1007/s00345-022-04005-3

Ejemplares similares